PTCT - PTC THERAPEUTICS, INC.

64.39
-1.980   -3.075%

Share volume: 1,259,674
Last Updated: 03-03-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$66.37
-1.98
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
9%
Profitability 0%
Dept financing 16%
Liquidity 71%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-5.57%
1 Month
-12.88%
3 Months
-17.29%
6 Months
11.00%
1 Year
24.31%
2 Year
107.84%
Key data
Stock price
$64.39
P/E Ratio 
8.93
DAY RANGE
$63.49 - $67.07
EPS 
$8.58
52 WEEK RANGE
$35.95 - $87.50
52 WEEK CHANGE
$23.99
MARKET CAP 
6.099 B
YIELD 
N/A
SHARES OUTSTANDING 
82.775 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-07-2025
BETA 
2.12
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,319,909
AVERAGE 30 VOLUME 
$1,213,672
Company detail
CEO: Stuart W. Peltz
Region: US
Website: ptcbio.com
Employees: 1,410
IPO year: 2013
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

PTC Therapeutics focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; Tegsedi and Waylivra for the. treatment of rare diseases in Latin America and the Caribbean. PTC518 is being developed for Huntington's disease.

Recent news